Whole brain radiotherapy and stereotactic radiosurgery for patients with recursive partitioning analysis I and lesions &lt;5 cm<sup>3</sup>: A matched pair analysis

Viani, Gustavo Arruda; Silva, Lucas Bernardes Godoi da; Viana, Bruno Silveira; Rossi, Bruno Tiago; Suguikawa, Elton; Zuliani, Gisele

doi:10.4103/0973-1482.179092

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other nonrandomized Six studies [70][71][72][73][74][75] 51 studies [76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99] 18 studies [127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][142][143][144] Three studies [145][146][147] Abbreviation: RCTs, randomized controlled trials.…”

Section: Summary Of Key Trials Published Prior To 2008mentioning

confidence: 99%

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Vogelbaum

Brown

Messersmith

et al. 2022

JCO

419

222

View full text Add to dashboard Cite

PURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines .

show abstract

Section: Summary Of Key Trials Published Prior To 2008mentioning

confidence: 99%

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Vogelbaum

Brown

Messersmith

et al. 2022

JCO

419

222

View full text Add to dashboard Cite

show abstract

A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases

et al. 2020

View full text Add to dashboard Cite

Whole brain radiotherapy and stereotactic radiosurgery for patients with recursive partitioning analysis I and lesions <5 cm³: A matched pair analysis

Abstract: WBRT plus SRS was an independent prognostic factor for survival. However, the combined treatment appears to be justified only in patients with RPA I and lesion volume ≤5 cm 3, independently of the number of lesions.

Cited by 2 publications

References 1 publication

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases

Contact Info

Product

Resources

About

Whole brain radiotherapy and stereotactic radiosurgery for patients with recursive partitioning analysis I and lesions <5 cm3: A matched pair analysis

Abstract: WBRT plus SRS was an independent prognostic factor for survival. However, the combined treatment appears to be justified only in patients with RPA I and lesion volume ≤5 cm 3, independently of the number of lesions.

Cited by 2 publications

References 1 publication

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases

Contact Info

Product

Resources

About

Whole brain radiotherapy and stereotactic radiosurgery for patients with recursive partitioning analysis I and lesions <5 cm³: A matched pair analysis